leisure time -WSS

leisure time

author：knowledge 2025-09-29 16:36:20 - browse：79313

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： What American doctors can learn from their Israeli counterparts

leisure time

WSS

Snackable artificial intelligence, expert AI, and the pharma industry

How to fix cancer clinical trials' diversity problem

Cue Health, Covid

How to fix cancer clinical trials' diversity problem

H5N1 virus can be tracked in retail milk, scientists say

FDA poised to publish guidelines for clinical trial diversity

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Snackable artificial intelligence, expert AI, and the pharma industry

New air purifier tech could be key to improving indoor air quality

ALS advocates say criticism of new drugs misses bigger picture

Dobbs anniversary: the lost opportunity of abortion as health care

'Make People Better': The CRISPR babies story you probably don't know

In age of alternative facts, a scholarly course on calling out crap

Liver decline slowed by off

Jerome Adams on the need for new antivirals for Covid

Stem cell treatment guidelines are released by FDA

entertainment

Crinetics acromegaly drug succeeds in late

Liver decline slowed by off

Study finds gene variants tied to breast cancer risk in Black women

'Make People Better': The CRISPR babies story you probably don't know

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Eyeing GLP

entertainment

hotspot

leisure time

hotspot